1. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis;Arnott;J Am Heart Assoc,2020
2. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis;Neuen;Lancet Diabetes Endocrinol,2019
3. US Food and Drug Administration: Jaridance. Highlights of prescribing information. Report number 40218852016, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf. Accessed January 21, 2021
4. US Food and Drug Administration: Steglatro. Highlights of prescribing information. Report number 41977462017, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf. Accessed January 21, 2021
5. US Food and Drug Administration: Invokana. Highlights of drug prescribing information. Report number 43417832018, 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf. Accessed January 21, 2021